Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development potential of rifalazil.

David M Rothstein1, Arthur D Hartman, Michael H Cynamon

  • 1ActivBiotics, Inc., 198 Broadway, Cambridge, MA 02139, USA. drothstein@activbiotics.com

Expert Opinion on Investigational Drugs
|January 31, 2003
PubMed
Summary

Rifalazil, a novel ansamycin, shows broad antimicrobial potential against intracellular pathogens like Chlamydia trachomatis and Chlamydia pneumoniae, and bacteria such as Helicobacter pylori and Clostridium difficile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection.

Kidney360·2026
Same author

BLIMP1 shapes germinal center B cell clonal diversity by gating chromatin accessibility during light-to-dark zone transition.

Nature immunology·2026
Same author

PRDM1 shapes germinal center B-cell clonal diversity by gating chromatin accessibility during light-to-dark zone transition.

bioRxiv : the preprint server for biology·2025
Same author

Donor-recipient mismatch at the <i>SIRPA</i> locus adversely affects kidney allograft outcomes.

Science translational medicine·2025
Same author

Author Correction: B-cell-specific checkpoint molecules that regulate anti-tumour immunity.

Nature·2025
Same author

Is Pathogen Molecular Testing Reshaping Outpatient Antibiotic Prescribing?

American journal of medical quality : the official journal of the American College of Medical Quality·2025

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Rifalazil is a novel ansamycin antibiotic with a unique four-ring structure.
  • It was initially developed as a tuberculosis treatment to replace rifampin.
  • Its properties suggest potential beyond tuberculosis treatment.

Purpose of the Study:

  • To explore the therapeutic potential of rifalazil against various bacterial and intracellular pathogens.
  • To assess rifalazil's efficacy in treating Chlamydia trachomatis, Chlamydia pneumoniae, Helicobacter pylori, and Clostridium difficile infections.

Main Methods:

  • The study focuses on the antimicrobial activity and intracellular levels of rifalazil.
  • Potential therapeutic applications are being evaluated based on its spectrum of activity.

Related Experiment Videos

  • Human clinical trials are planned to assess its value in treating specific indications.

    • Main Results:

    • Rifalazil exhibits superior antimicrobial activity compared to traditional treatments.
    • It achieves high intracellular levels, crucial for targeting intracellular pathogens.
    • Its favorable antimicrobial spectrum indicates broad applicability.

    Conclusions:

    • Rifalazil demonstrates significant potential for treating infections caused by Chlamydia trachomatis and Chlamydia pneumoniae.
    • It may be a valuable therapeutic option for Helicobacter pylori and Clostridium difficile infections.
    • Further human clinical trials are necessary to confirm its efficacy and safety in these indications.